Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.48 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.48 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.48 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.40 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.40 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.40 |
| ▸ | KCNQ1 | P51787 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | RARA | P10276 | 1/20 | 0.36 |
| ▸ | RARB | P10826 | 1/20 | 0.36 |
| ▸ | RARG | P13631 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17792180 | 0.91 | KCNQ3 (0.40) | TAS1R3TAS1R1TAS1R2KCNQ3KCNQ2 | |
| SCHEMBL19473184 | 0.88 | TAS1R3 (0.42) | TAS1R3TAS1R1TAS1R2KCNQ3KCNQ2 | |
| SCHEMBL17792133 | 0.86 | TAS1R3 (0.47) | TAS1R3TAS1R1TAS1R2KCNQ3KCNQ2 | |
| SCHEMBL19473175 | 0.86 | KCNQ3 (0.37) | TAS1R3TAS1R1TAS1R2KCNQ3KCNQ2 | |
| SCHEMBL17792132 | 0.86 | BRD4 (0.41) | TAS1R3TAS1R1TAS1R2KCNQ3KCNQ2 | |
| SCHEMBL19473186 | 0.85 | MAOB (0.42) | TAS1R3TAS1R1TAS1R2KCNQ3KCNQ2 | |
| SCHEMBL19473185 | 0.83 | KMT2A (0.47) | KCNQ3KCNQ2MAPTALDH1A1LMNA | |
| SCHEMBL17816178 | 0.82 | CYP1A2 (0.35) | TAS1R3TAS1R1TAS1R2KCNQ3KCNQ2 | |
| SCHEMBL17792077 | 0.78 | LMNA (0.39) | KCNQ3KCNQ2KCNE1KCNQ1CYP2C9 | |
| SCHEMBL17784102 | 0.78 | MAPT (0.45) | TAS1R3TAS1R1TAS1R2KCNQ3KCNQ2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160151375-A1 | SULFIDE ALKYL COMPOUNDS FOR HBV TREATMENT | NOVIRA THERAPEUTICS, INC. | 2016-06-02 | — | — | US | disclosed |
| US-20160151375-A1 | SULFIDE ALKYL COMPOUNDS FOR HBV TREATMENT | NOVIRA THERAPEUTICS, INC. | 2016-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160151375-A1 | SULFIDE ALKYL COMPOUNDS FOR HBV TREATMENT | HAVCR2, HCCS, CBS | TAS1R3 3605/4885TAS1R1 3692/4885TAS1R2 3818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.